Biotech industry worries over potential for RFK Jr. ally as FDA pick
US presidential election winner Donald Trump has promised to let his ally Robert F. Kennedy Jr. “go wild” on drug and food policy. While Kennedy’s exact role in a potential Trump administration is...
View ArticleMacroGenics pauses development of ADC; Cellectis deprioritizes CAR-T
Plus, news about Tango Therapeutics, Endo, Neurogene and Century Therapeutics: MacroGenics stopped dosing patients in ADC trial: After three patient deaths in a Phase 2 prostate cancer drug trial for...
View ArticleCVS names Aetna head, plans more pharmacy closures as new CEO takes over
In his first quarter leading CVS Health, CEO David Joyner laid out the initial steps he’s taking to rightsize the company, as challenges continue to plague its insurance business. As part of those...
View ArticleStudies show how once-obscure DNA circles drive cancer, and maybe even how to...
Scientists have unveiled a strategy for targeting a vulnerability in tiny circles of floating DNA that can drive aggressive cancers. These circles — known as extrachromosomal DNA, or ecDNA, because...
View ArticleQ&A: GSK’s CEO Emma Walmsley on the new Trump administration, trust, AI and...
Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley believes her company can work “constructively” with the incoming...
View ArticleCalifornia voters say yes to restrictions around 340B spending
California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug discount program. According to unofficial results, 51.5% of voters said yes to...
View ArticleSarepta discontinues work on next-gen exon-skipping drug for Duchenne
Sarepta Therapeutics is stopping development of vesleteplirsen, an experimental exon 51-skipping therapy for Duchenne muscular dystrophy patients with certain mutations. It's also halting work on all...
View ArticleModerna reports $10M in first RSV sales, a slow start for new vaccine
Moderna revealed the consequences of its late start in the market for RSV vaccines, reporting just $10 million in third-quarter sales from the new shot. Those numbers are a fraction of the $600 million...
View ArticleJoe Jimenez's latest Aditum company lines up T cell engager from China
Joe Jimenez's Aditum Bio, an investment firm that builds companies around in-licensed assets, is going after one of the hottest new areas for its latest startup. The Oakland, CA-based firm is setting...
View ArticleArcus backs TIGIT combo by offering glimpse at positive data from axed trial
Arcus Biosciences unveiled data from a terminated late-stage study of its TIGIT and PD-1 drug combo that it says supports its decision to take the approach forward in a different lung cancer setting....
View ArticleGilead beats Covid drug sales forecasts, takes $1.75B hit on Trodelvy study fail
Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall Street analysts had projected. Gilead’s shares {$GILD} were up 3% in after ...
View ArticleHow Menlo Ventures thinks AI in health tech is going to be commoditized
While there’s a lot of potential for AI in health tech, it will soon be commoditized, investor Greg Yap told Endpoints News in an interview on the sidelines of the HLTH conference in Las Vegas ...
View ArticleAvid Bioservices to be sold to private equity firms for $1.1B
After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion. “In evaluating this...
View ArticleNobel winner Demis Hassabis talks next steps for AI in biology
LONDON — Demis Hassabis is pursuing one of the boldest efforts of bringing AI into biotech, building out the Alphabet-backed startup Isomorphic Labs over the past three years. In an exclusive sitdown ...
View ArticleDenali teases early data for enzyme replacement therapy in rare disease
Denali revealed new topline data Wednesday for an early-stage program that's a part of the FDA’s Operation Warp Speed for rare diseases. The program, DNL126, is an enzyme replacement therapy for...
View ArticleGeron’s royalty deal; Minghui’s new VEGF bispecific data
Plus, news about ADC Therapeutics, Celldex and Viracta Therapeutics: Geron inks up to $375M royalty and debt deal: The company now has a $125 million deal with Royalty Pharma based on ...
View ArticleAurinia cuts nearly half of its workforce in second round of layoffs this year
Aurinia Pharmaceuticals is reducing 45% of its workforce and is bringing in a new board member as part of a broader restructuring. The company announced the layoffs on ...
View ArticleGenmab chops early cancer prospects to prioritize Phase 3 projects
Genmab is culling a trio of early oncology assets to focus on upcoming milestones for its late-stage programs that include an ADC from its purchase of ProfoundBio. After “careful consideration,” Genmab...
View ArticleCoherus restarts biosimilar supply after delays; Novavax ends Covid vaccine...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its Neulasta biosimilar after...
View ArticleFDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacy
After 17 years of back and forth with citizen petitions and two advisory committees, the FDA on Thursday proposed to pull commonly-used nasal decongestant active ingredients in common over-the-counter...
View ArticleVaccine makers face headwinds from RFK, soft demand and China
Coming out of Covid, the vaccine market appeared to experience a renaissance as the innovations of the pandemic unleashed new products and a new impetus to prevent infections. But just a few years...
View ArticleStephen Squinto's JPM life sciences team is raising a new fund for...
CHICAGO — Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a second fund geared toward more growth-stage opportunities. ...
View ArticleSenior AstraZeneca exec detained in China amid wider investigation
The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his detainment, Leon Wang, executive vice president of international and president...
View ArticlePfizer to invest $1B in China over next five years — reports
Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a new phase of growth. Pfizer China President Jean-Christophe Pointeau said ...
View Article